Evolutionary Genomics, Inc.
Evolutionary Genomics, Inc. (FNAM) Revenue
Annual & quarterly revenue history · segment & region breakdown
FNAM · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsEvolutionary Genomics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2009 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | -$0.00B | -89.81% |
| 2019-12-31 | $0.00B | +$0.00B | +6.86% |
| 2018-12-31 | $0.00B | +$0.00B | +251.22% |
| 2017-12-31 | $0.00B | -$0.00B | -85.25% |
| 2016-12-31 | $0.00B | -$0.00B | -15.72% |
| 2015-12-31 | $0.00B | -$0.00B | -24.45% |
| 2014-12-31 | $0.00B | -$0.00B | -56.44% |
| 2013-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Evolutionary Genomics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Evolutionary Genomics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Evolutionary Genomics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FNAM revenue · 4 questionsFNAM's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Evolutionary Genomics, Inc. SEC filings · GAAP · Evolutionary Genomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026